In this study, we aimed to compare the efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC.<h4>Methods</h4>The electronic databases were systematically searched from inception until March 18, 2024. Here, EGFR is linked to non-small cell lung carcinoma.